


## Participant Flow



## Baseline Demographics

Site 1010 (Manchester University)		Total (n=48)
<b>Age (years)</b>		
	Mean (SD)	64 (16)
	Median	68
	Range	24-90
<b>Gender</b>		
	Female	21 (44%)
	Male	27 (56%)
<b>Weight (kg)</b>		
	Missing	2
	Mean (SD)	80 (19)
	Median	74
	Range	44-133
<b>Height (cm)</b>		
	Missing	5
	Mean (SD)	167 (12)
	Median	167
	Range	124-197
<b>BMI (kg/m<sup>2</sup>)</b>		
	Missing	5
	Mean (SD)	29 (7)
	Median	28
	Range	18-47
<b>Subject Smoking Status</b>		
	Never	18 (38%)
	Current (smoking within the last month)	10 (21%)
	Former	20 (42%)
<b>Alcoholic Drinks per week</b>		
	None	23 (48%)
	Any	25 (52%)
<b>Comorbid conditions</b>		
	Diabetes	7 (15%)
	Coronary Heart Disease	3 (6%)
	Steroid Use	1 (2%)
	Hypertension	13 (27%)
	Other	20 (42%)

## Outcome Measures

### Primary Endpoint - Safety

#### Summary of All Treatment Related Adverse Events (TRAEs) by System Organ Class and Preferred Term

	Total N=48	
	Events	Subjects (%)
All TRAE	2	2 (4%)
Infections and infestations	1	1 (2%)
Infection	1	1 (2%)
Skin and subcutaneous tissue disorders	1	1 (2%)
Dermatitis contact	1	1 (2%)

Note: Adverse events were coded using MedDRA version v22.0 Subjects were counted once in each event.

## Secondary Endpoint – Wound Healing

### Treatment Outcomes at End of Treatment (n=48)

---

#### Days from treatment initiation to conclusion

Mean (SD)	14.8 (5.3)
Median	14
Q1, Q3	11, 20
Range	4 - 24
1-7	6 (13%)
8-14	19 (40%)
15-21	21 (44%)
>21	2 (4%)

#### Wound Condition

Improved	39 (81%)
Unchanged	5 (10%)
Deteriorating	3 (6%)
Blank	1 (2%)

#### Wound Reduced (volume, area, or depth)

Missing	2 (4%)
No	3 (6%)
Yes	43 (90%)

#### Nonviable Tissue Reduced

Missing	2 (4%)
No	37 (77%)
Yes	9 (19%)

#### Granulation Increased

Missing	2 (4%)
No	37 (77%)
Yes	9 (19%)

#### Moisture Level

Non-Optimal Moisture	22 (46%)
Optimal Moisture	26 (54%)

#### Secondary Objective Outcome (Healing Promoted)

Secondary Endpoint NOT Met	4 (8%)
Secondary Endpoint Met	44 (92%)

---